Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D W Beelen

Showing results (21-30 of 99) with videos related to

Pageof 10
Sort By:
Blood|July 9, 1999
The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrowA H Elmaagacli, D W Beelen, B Opalka, et al.
Annals of Hematology|September 14, 2000
The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stageA H Elmaagacli, D W Beelen, B Opalka, et al.
Blood|October 1, 1996
Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrowH D Ottinger, D W Beelen, B Scheulen, et al.
Beitrage Zur Infusionstherapie = Contributions to Infusion Therapy|January 1, 1990
[Erythrocyte substitution and isoagglutinin titer following ABO-incompatible bone marrow transplantation]K B Henneberg-Quester, W Luboldt, U W Schaefer, et al.
Bone Marrow Transplantation|February 26, 2013
Bronchiolitis obliterans after allogeneic hematopoietic SCT: further insight--new perspectives?M Ditschkowski, A H Elmaagacli, M Koldehoff, et al.
Deutsche Medizinische Wochenschrift (1946)|May 16, 1986
[alpha 2-interferon: preliminary treatment results in chronic myeloid leukemia]N Niederle, O Kloke, C Doberauer, et al.
Histology and Histopathology|February 24, 2001
Bone marrow engraftment: histopathology of hematopoietic reconstitution following allogeneic transplantation in CML patientsJ Thiele, H M Kvasnicka, D W Beelen, et al.
Bone Marrow Transplantation|May 7, 1999
Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantationA H Elmaagacli, D W Beelen, G Trenn, et al.
European Journal of Haematology|June 9, 2004
Disease- or therapy-related bone marrow damage cannot be overcome by changes in stem cell source or dose in allogeneic transplantationJ R Novotny, C Rosenthal, A H Elmaagacli, et al.
Bone Marrow Transplantation|August 8, 2007
Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantationA H Elmaagacli, M Koldehoff, N K Steckel, et al.
Pageof 10

Showing results (21-30 of 99) with videos related to

Sort By:
Pageof 10
Blood|July 9, 1999
The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrowA H Elmaagacli, D W Beelen, B Opalka, et al.
Annals of Hematology|September 14, 2000
The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stageA H Elmaagacli, D W Beelen, B Opalka, et al.
Blood|October 1, 1996
Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrowH D Ottinger, D W Beelen, B Scheulen, et al.
Beitrage Zur Infusionstherapie = Contributions to Infusion Therapy|January 1, 1990
[Erythrocyte substitution and isoagglutinin titer following ABO-incompatible bone marrow transplantation]K B Henneberg-Quester, W Luboldt, U W Schaefer, et al.
Bone Marrow Transplantation|February 26, 2013
Bronchiolitis obliterans after allogeneic hematopoietic SCT: further insight--new perspectives?M Ditschkowski, A H Elmaagacli, M Koldehoff, et al.
Deutsche Medizinische Wochenschrift (1946)|May 16, 1986
[alpha 2-interferon: preliminary treatment results in chronic myeloid leukemia]N Niederle, O Kloke, C Doberauer, et al.
Histology and Histopathology|February 24, 2001
Bone marrow engraftment: histopathology of hematopoietic reconstitution following allogeneic transplantation in CML patientsJ Thiele, H M Kvasnicka, D W Beelen, et al.
Bone Marrow Transplantation|May 7, 1999
Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantationA H Elmaagacli, D W Beelen, G Trenn, et al.
European Journal of Haematology|June 9, 2004
Disease- or therapy-related bone marrow damage cannot be overcome by changes in stem cell source or dose in allogeneic transplantationJ R Novotny, C Rosenthal, A H Elmaagacli, et al.
Bone Marrow Transplantation|August 8, 2007
Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantationA H Elmaagacli, M Koldehoff, N K Steckel, et al.
Pageof 10